Retina Action Call to Action launch
Author: Claire Duggan
REGENXBIO Update on RGX-314 treatment for wet AMD
Retina International Winter 2020 Newsletter now available
Success for Roche’s faricimab at phase 3 clinical trials for treatment of DME
Janssen Acquires Rights to Novel Gene Therapy for Late-Stage AMD
From Bench to Bedside: The journey to creating a sight-saving drug
Retina International COVID-19 Impact survey pt.2 now open!
MeiraGTx Investigational Gene Therapy leads to improved vision in patients with XLRP after 1 year
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company
SparingVision Announces new funding and CEO.
CRISPR success for IRDs in mice
Luxturna is first ever gene therapy to be approved in Canada.
-
close